Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20814


Purpose:

This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. Each patient's participation will last approximately 41 weeks.


Criteria:

Inclusion Criteria: - Diagnosis of probable Alzheimer's Disease with MMSE score of 16-26, and brain MRI consistent with the diagnosis of Alzheimer's Disease - Concurrent use of cholinesterase inhibitor or memantine allowed, if stable. - Caregiver will participate and be able to attend clinic visits with patient Exclusion Criteria: - Significant neurological disease other than Alzheimer's Disease - Major psychiatric disorder - Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body) - Women of childbearing potential


NCT ID:

NCT01193608


Primary Contact:

Study Director
Pfizer CT.gov Call Center
Pfizer


Backup Contact:

N/A


Location Contact:

Bethesda, Maryland 20814
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.